Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALACE: Serplulimab + Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT07020247Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2024
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in rectal cancer, sponsored by West China Hospital of Sichuan University. Started Nov 2024; status: recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07020247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020247.